Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of Intravenous PCN-101 in Treatment Resistant Depression

To see complete record on, please visit this link

Id: NCT05414422

Organisation Name: Perception Neuroscience

Overal Status: Active, not recruiting

Start Date: February 1, 2022

Last Update: November 1, 2022

Lead Sponsor: Perception Neuroscience

Brief Summary: This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks [Day -15 to Day -2]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment [Day 1]), and post-treatment follow-up (7 and 14 days after infusion on Days 8 and 15, respectively). A total of 93 adult subjects with TRD will be randomly allocated in equal cohorts of 31 subjects/arm to the 3 arms of the study in a blinded manner.

  • Treatment Resistant Depression

Total execution time in seconds: 0.20541882514954